Spyridon Alexis
Overview
Explore the profile of Spyridon Alexis including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
6
Citations
9
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Plakoula E, Kalampounias G, Alexis S, Verigou E, Kourakli A, Zafeiropoulou K, et al.
Curr Issues Mol Biol
. 2025 Jan;
47(1).
PMID: 39852147
Proteasome inhibitors (PIs) constitute the most common type of induction treatment for multiple myeloma. Interactions between the proteasome, autophagy, and reactive oxygen species (ROS) have been shown in the past,...
2.
Chatzilygeroudi T, Chondrou V, Boers R, Siamoglou S, Athanasopoulou K, Verigou E, et al.
Clin Epigenetics
. 2024 Jun;
16(1):79.
PMID: 38879530
Background: As new treatment options for patients with higher-risk myelodysplastic syndromes are emerging, identification of prognostic markers for hypomethylating agent (HMA) treatment and understanding mechanisms of their delayed and short-term...
3.
Zafeiropoulou K, Kalampounias G, Alexis S, Anastasopoulos D, Symeonidis A, Katsoris P
PLoS One
. 2024 Feb;
19(2):e0289904.
PMID: 38412186
Proteasome inhibitors such as Bortezomib represent an established type of targeted treatment for several types of hematological malignancies, including multiple myeloma, Waldenstrom's macroglobulinemia, and mantle cell lymphoma, based on the...
4.
Kalampounias G, Gardeli C, Alexis S, Anagnostopoulou E, Androutsopoulou T, Dritsas P, et al.
J Fungi (Basel)
. 2024 Feb;
10(2).
PMID: 38392802
NRRL-1393 is an oleaginous fungus able to synthesize and accumulate unsaturated fatty acids, amongst which the bioactive gamma-linolenic acid (GLA) has potential anti-cancer activities. was cultured in shake-flask nitrogen-limited media...
5.
Zafeiropoulou K, Kalampounias G, Alexis S, Androutsopoulou T, Katsoris P, Symeonidis A
Cureus
. 2024 Jan;
15(12):e49843.
PMID: 38169896
Myelodysplastic syndromes (MDS) constitute a heterogeneous group of clonal hematopoietic stem cell disorders characterized by ineffective hematopoiesis and an elevated risk of transformation to acute myeloid leukemia (AML). Available disease-modifying...
6.
Matsagos S, Verigou E, Kourakli A, Alexis S, Vrakas S, Argyropoulou C, et al.
Front Med (Lausanne)
. 2022 Mar;
9:845490.
PMID: 35252277
Background: Transfusion-associated microchimerism implies the presence of allogeneic hematopoietic cells in an individual, following the transfusion of a blood product. It is a transfusion-related adverse effect/long-term consequence, which has not...
7.
Theofani E, Alexis S, Costeas P, Andriopoulos C, Feleskoura G, Zikos P, et al.
Blood Adv
. 2018 Apr;
2(8):877-882.
PMID: 29669754
No abstract available.